Penny Stock News Trending Stock News

Immune Pharmaceuticals Inc. (IMNP) Reaches $0.26 Yearly Low; Skyline Asset Management LP Boosted Its Aarons (AAN) Position

Aaron's, Inc. (NYSE:AAN) Logo

Skyline Asset Management Lp increased Aarons Inc (AAN) stake by 8.11% reported in 2017Q4 SEC filing. Skyline Asset Management Lp acquired 45,600 shares as Aarons Inc (AAN)’s stock rose 12.82%. The Skyline Asset Management Lp holds 608,200 shares with $24.24 million value, up from 562,600 last quarter. Aarons Inc now has $2.89B valuation. The stock increased 1.38% or $0.56 during the last trading session, reaching $41.14. About 41,834 shares traded. Aaron's, Inc. (NYSE:AAN) has risen 57.60% since May 17, 2017 and is uptrending. It has outperformed by 46.05% the S&P500.

The stock of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) hit a new 52-week low and has $0.24 target or 8.00% below today’s $0.26 share price. The 5 months bearish chart indicates high risk for the $8.23 million company. The 1-year low was reported on May, 17 by Barchart.com. If the $0.24 price target is reached, the company will be worth $658,720 less. The stock increased 1.22% or $0.0031 during the last trading session, reaching $0.2581. About 283,823 shares traded. Immune Pharmaceuticals Inc. (NASDAQ:IMNP) has declined 87.86% since May 17, 2017 and is downtrending. It has underperformed by 99.41% the S&P500.

Among 4 analysts covering Immune Pharma (NASDAQ:IMNP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Immune Pharma had 4 analyst reports since October 8, 2015 according to SRatingsIntel. The stock has “Buy” rating by TH Capital on Thursday, October 8. As per Thursday, October 8, the company rating was initiated by Roth Capital. The firm earned “Buy” rating on Tuesday, October 13 by Chardan Capital Markets.

More recent Immune Pharmaceuticals Inc. (NASDAQ:IMNP) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018. Also Streetinsider.com published the news titled: “Immune Pharma (IMNP) Highlights Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid” on May 15, 2018. Nasdaq.com‘s news article titled: “Immune Pharmaceuticals Presents Updated Positive Results from Phase 2 Trial of Bertilimumab in Bullous Pemphigoid” with publication date: May 15, 2018 was also an interesting one.

Immune Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company has market cap of $8.23 million. The companyÂ’s lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohnÂ’s, and ulcerative colitis diseases. It currently has negative earnings. It also develops NanoCyclo, a topical nanocapsule formulation of cyclosporine-A, which is in preclinical stage for the treatment of atopic dermatitis and psoriasis.

Skyline Asset Management Lp decreased Virtusa Corp (NASDAQ:VRTU) stake by 143,400 shares to 456,500 valued at $20.12M in 2017Q4. It also reduced Materion Corp (NYSE:MTRN) stake by 250,715 shares and now owns 229,185 shares. Winnebago Inds Inc (NYSE:WGO) was reduced too.

Among 14 analysts covering Aaron’s Inc (NYSE:AAN), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Aaron’s Inc had 38 analyst reports since July 28, 2015 according to SRatingsIntel. The company was downgraded on Thursday, October 29 by KeyBanc Capital Markets. The rating was upgraded by Loop Capital to “Buy” on Wednesday, November 8. Raymond James maintained the stock with “Buy” rating in Tuesday, February 20 report. The firm earned “Buy” rating on Friday, February 16 by SunTrust. The stock of Aaron's, Inc. (NYSE:AAN) earned “Buy” rating by Jefferies on Thursday, October 13. Topeka Capital Markets initiated Aaron's, Inc. (NYSE:AAN) on Tuesday, May 24 with “Buy” rating. Jefferies maintained Aaron's, Inc. (NYSE:AAN) on Thursday, June 15 with “Buy” rating. Stifel Nicolaus maintained it with “Buy” rating and $55 target in Monday, July 31 report. The rating was upgraded by Suntrust Robinson to “Buy” on Friday, January 20. The company was maintained on Friday, July 28 by Stifel Nicolaus.

Since February 27, 2018, it had 0 buys, and 9 insider sales for $4.50 million activity. Another trade for 15,000 shares valued at $634,050 was sold by Doman Curtis Linn. 452 shares were sold by SINCLAIR ROBERT P JR, worth $22,148 on Monday, March 12. Robinson John W also sold $742,525 worth of Aaron's, Inc. (NYSE:AAN) shares. Michaels Steven A also sold $425,600 worth of Aaron's, Inc. (NYSE:AAN) shares. $1.92M worth of Aaron's, Inc. (NYSE:AAN) shares were sold by Yanker Robert H. Kamerschen Robert W. sold $84,760 worth of stock or 2,000 shares. The insider Woodley Ryan K sold $529,375.

Aaron's, Inc. (NYSE:AAN) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *